Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production.
Wight NJ, Gottesdiener K, Garlick NM, Atherton CT, Novak S, Gertz BJ, Calder NA, Cote J, Wong P, Dallob A, Hawkey CJ.
Wight NJ, et al. Among authors: atherton ct.
Gastroenterology. 2001 Mar;120(4):867-73. doi: 10.1053/gast.2001.22432.
Gastroenterology. 2001.
PMID: 11231941
Clinical Trial.